SUBSCRIBE TO TMCnet
TMCnet - World's Largest Communications and Technology Community

TMC NEWS

TMCNET eNEWSLETTER SIGNUP

Our Members Know First!! BOFL,AGYS,MBCI,BCRX,BCSI,BNVI
[November 06, 2009]

Our Members Know First!! BOFL,AGYS,MBCI,BCRX,BCSI,BNVI


(M2 PressWIRE Via Acquire Media NewsEdge) STOCK MARKETING INC PRESENTS : (NASDAQ: BOFL - Bank of Florida Corp.) (NASDAQ: AGYS - Agilysys, Inc.) (OTCBB: MBCI - MabCure, Inc.) (NASDAQ: BCRX - BioCryst Pharmaceuticals, Inc.) (NASDAQ: BCSI - Blue Coat Systems, Inc.) (NASDAQ: BNVI - BioNovo, Inc..) www.StockMarketingInc.com To sign up for our free Profiles & Alerts :: visit http://www.StockMarketingInc.com email us!! info@StockMarketingInc.com or call 1-866-583-8960 ------------------------------------------------------------------------------------------------------------------------------------------------------------ (NASDAQ: BOFL - Bank of Florida Corp.) LATEST NEWS!! Bank of Florida Announces Public Offering NAPLES, Fla., Nov 05, 2009 -- Bank of Florida Corporation (Nasdaq: BOFL) (the "Company") today announced that it has commenced an offering to sell shares of its common stock in an underwritten public offering. Raymond James & Associates, Inc. is acting as the lead book-running manager for the offering. Sandler O'Neill & Partners, L.P., Allen & Company LLC and Stifel, Nicolaus & Company, Incorporated are acting as co-managers for the offering. The Company intends to grant the underwriters an option to purchase additional shares equal to 15% of the numbers of shares offered to the public.



The Company expects to use approximately $71 million of the net proceeds from the offering to capitalize its subsidiary banks pursuant to regulatory agreements regarding projected capital levels as of December 31, 2009. In addition, the Company expects to use a portion of the net proceeds of the offering to redeem any shares of its outstanding Series B Preferred Stock that are not converted by the holders of the Series B Preferred Stock according to its terms.

A registration statement relating to shares of the Company's common stock to be sold in the offering has been filed with the Securities and Exchange Commission ("SEC") but has not yet become effective. The registration statement also covers shares of the Company's common stock issuable upon conversion of shares of its Series B Preferred Stock that are not redeemed for cash as described above. None of the shares of common stock covered by the registration statement may be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. The registration statement on Form S-1 may be accessed through the SEC's website at www.sec.gov. Alternatively, copies of the prospectus relating to the offering may be obtained from Raymond James & Associates, Inc. at 880 Carillon Parkway, St. Petersburg, FL 33716 or by telephone at (727) 567-2400.


Bank of Florida Corporation Bank of Florida Corporation (Nasdaq: BOFL) is a $1.6 billion-asset multi-bank holding Company located in Naples, Florida. Bank of Florida Corporation is the parent company for Bank of Florida - Southwest in Collier and Lee Counties; Bank of Florida - Southeast in Broward, Miami-Dade and Palm Beach Counties; Bank of Florida - Tampa Bay in Hillsborough and Pinellas Counties; and Bank of Florida Trust Company. Investor information may be found on the Company's web site, http://www.bankofflorida.com ------------------------------------------------------------------------------------------------------------------------------------------------------------ (NASDAQ: AGYS - Agilysys, Inc.) LATEST NEWS!! Agilysys and Global Bay Mobile Technologies Partner to Provide Unique Mobility Solutions to Retailers and Additional Industries --Solutions to help retailers and other industries leverage mobile technologies to increase operational efficiencies and enhance customer service CLEVELAND and SOUTH PLAINFIELD, N.J., Nov 05, 2009 -- Agilysys, Inc. (Nasdaq: AGYS), a leading provider of innovative IT solutions, and Global Bay Mobile Technologies, Inc., a leading provider of operational and customer-facing mobility solutions, today announced a partnership to deliver advanced and secure mobile applications focused on enhancing overall operations for its retail customers and to address the growing retail-to-consumer mobile application market. The in-store solutions deployed by Agilysys and Global Bay will assist store associates with functions such as task management, inventory transfers and stock management, ultimately helping improve the efficiency of a retailer's store operations and their ability to manage overall inventory. Using Global Bay's customer facing mobile capabilities and advanced technologies will also empower Agilysys to enhance a retailer's interactions with their customers.

(Logo: http://www.newscom.com/cgi-bin/prnh/20030915/AGLSLOGO ) "Realizing wireless and mobility solutions are playing an increasing role in store operations and consumer-facing self-service, we are excited to partner with a leading mobility technology company like Global Bay to expand our current mobile application offerings, development and services capabilities," said Paul Civils, senior vice president and general manager of Agilysys Retail Solutions Group. "The benefits of our combined solution offerings extend beyond the store associate to retail executives, providing access to key performance indicators and data related to individual store performance. Access to this real-time information is extremely valuable, especially given today's retail climate." Global Bay's mobility technologies and offerings will enhance Agilysys' ability to develop and deploy applications on Motorola wireless devices, as well as extending these applications to devices such as Blackberry(R) smartphones, the Apple iPhone(R) mobile digital device and Apple iPod touch(R) mobile digital device.

In addition, this partnership will enable Agilysys to extend its mobility solutions and service offerings beyond the retail industry to markets such as healthcare, government and transportation. The combination of Global Bay mobile software technologies and Agilysys' mobile capabilities, including hardware sourcing, development and integration, staging, monitoring and management, is uniquely suited to address the needs of a broad range of customers, both inside and outside the retail industry.

"We are proud to announce this partnership as we continue to grow our market share in the dynamic retail marketplace," said Sandeep Bhanote, chief executive officer of Global Bay Mobile Technologies. "Agilysys has established impressive credentials in the retail industry in IT services and mobile solutions and we look forward to delivering the next generation of mobility software solutions with them." The synergy of this partnership is expected to leverage the retail and mobility expertise of both companies and serve as an essential foundation in the pursuit of joint research and development of new applications. Additionally, through these combined solution offerings, the companies anticipate expanding their footprint within and beyond the retail industry. And notably, with these solutions Agilysys reinforces its "one-stop-shop" and systems integration capabilities, offering customers more complete overall and secure mobility solutions which include development, deployment, ongoing security and management throughout the entire solution lifecycle.

About Agilysys, Inc.

Agilysys is a leading provider of innovative IT solutions to corporate and public-sector customers, with special expertise in select markets, including retail and hospitality. The company uses technology -- including hardware, software and services -- to help customers resolve their most complicated IT needs. The company possesses expertise in enterprise architecture and high availability, infrastructure optimization, storage and resource management, identity management and business continuity; and provides industry-specific software, services and expertise to the retail and hospitality markets. Headquartered in Cleveland, Agilysys operates extensively throughout North America, with additional sales and support offices in the United Kingdom and China. For more information, visit www.agilysys.com.

------------------------------------------------------------------------------------------------------------------------------------------------------------ (OTCBB: MBCI - MabCure, Inc.) LATEST NEWS!! MABCURE N.V. Signs Research Agreement With AZ Sint Lucas Hospital, Brugge, Belgium, to Conduct Preclinical Research on its Monoclonal Antibodies (Mabs) against Different Cancers Research Intended to Broaden the Utility of MabCure's Mabs for Cancer Diagnosis in Tissue Specimen HASSELT, Belgium, Nov 04, 2009 -- MabCure N.V., a subsidiary of MabCure Inc. (OTC BB: MBCI), a biotech company that has developed a series of highly specific monoclonal antibodies (Mabs) to combat various types of cancers, has signed a research agreement with AZ Sint Lucas Hospital, Brugge, Belgium. AZ Sint Lucas Hospital will conduct preclinical research intended to broaden the utility of MabCure's monoclonal antibodies for those circumstances where there is a need to diagnose cancer in tissue specimen. At present, the Company's Mabs for the diagnosis of ovarian cancer, prostate cancer and colorectal cancer, for example, are aimed at diagnosing early stage disease in physiological samples such as urine and serum.

Dr. Amnon Gonenne, CEO of MabCure Inc commented, "If this preclinical research works, it would open a door for us to diagnose everything that goes through surgery. This would include, for example, all of the at-risk melanoma patient population that routinely has moles removed prophylactically. The resection is arbitrary and there is currently no method to determine if the removed moles harbor early stage melanoma or not. This is critically important since melanoma is a highly lethal disease. MabCure's Mabs may provide a definitive diagnosis of early stage melanoma in these tissue specimens thereby allowing effective treatment of the patient. An analogous situation exists in colonoscopy where it is difficult to provide definitive diagnosis of early colon cancer in the resected polyps. This approach could be extended to other organs." Dr. Gonnene continued, "Currently, we address multibillion-dollar opportunities with the specimens we know our Mabs are effective against. This new opportunity would allow us to cast an even wider net and we are very excited about the possibility of helping these patients." Studies have already begun at AZ Sint Lucas Hospital, and all scientific results will remain a property of MabCure.

About AZ Sint Lucas Hospital The Saint Lucas General Hospital in Bruges is an independent hospital with emphasis on advanced patient care, active clinical research and participation in multi-center clinical trials.

About MabCure Inc.

MabCure is a biotechnology company whose vision is to change the perception of cancer as being a largely incurable disease. MabCure owns proprietary technology for the creation of unique and highly specific monoclonal antibodies (MAbs), which will be developed as diagnostic tools, imaging agents, and drugs to treat lethal cancers. MabCure initial goal is to develop its novel MAbs as diagnostic tools for the detection of Ovarian and Prostate cancers at an early stage, when these diseases are still localized and highly curable. For further information visit the Company's website www.mabcure.com.

------------------------------------------------------------------------------------------------------------------------------------------------------------ (NASDAQ: BCRX - BioCryst Pharmaceuticals, Inc.) LATEST NEWS!! BioCryst Receives First Peramivir Order From U.S. Government BIRMINGHAM, Ala., Nov 05, 2009 -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced it has received an initial order for 10,000 courses of intravenous (i.v.) peramivir (600 mg once-daily for five days) with a value of $22.5 million under a newly issued contract with the Department of Health and Human Services (HHS). On November 4, BioCryst shipped the entire order from existing i.v. peramivir inventory to HHS.

"BioCryst is pleased to deliver this initial U.S. Government order for peramivir for use under the Emergency Use Authorization, or EUA, to treat hospitalized adult and pediatric influenza patients who may benefit from peramivir," said Jon P. Stonehouse, President and Chief Executive Officer at BioCryst. "We expect to complete production of approximately 120,000 additional courses of i.v. peramivir by the end of December, and we are prepared to produce more if required to meet orders for the U.S. or other governments. BioCryst has been in contact with a number of governments around the world that are assessing i.v. peramivir for critically ill influenza patients." Under the Indefinite Delivery Indefinite Quantity contract issued to BioCryst on November 3, 2009, HHS may place additional orders for peramivir up to a total of 40,000 courses of i.v. peramivir at the same unit price as the first order. BioCryst is also required to maintain the ability to manufacture additional treatment courses dependent on the volume and size of anti-viral orders received from HHS.

About peramivir Peramivir is a potent, intravenously administered anti-viral agent that rapidly delivers high plasma concentrations to the sites of infection. Discovered by BioCryst, peramivir inhibits the interactions of influenza neuraminidase, an enzyme which is critical to the spread of influenza within a host. In laboratory tests, peramivir has shown activity against pandemic H1N1 swine flu origin viral strains. Peramivir has been studied in over 1,800 patients with complicated and uncomplicated influenza. On October 23, 2009, BioCryst announced that the U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for i.v. peramivir in certain adult and pediatric patients with confirmed or suspected 2009 H1N1 influenza infection who are admitted to a hospital. Additional information regarding the peramivir EUA is available on the web at: www.cdc.gov/h1n1flu/eua/.

About BioCryst BioCryst Pharmaceuticals designs, optimizes and develops novel small-molecule pharmaceuticals that block key enzymes involved in infectious diseases, cancer and inflammatory diseases. BioCryst has progressed two novel compounds into late-stage pivotal clinical trials; peramivir, an anti-viral for influenza, and forodesine, a purine nucleoside phosphorylase (PNP) inhibitor for cutaneous T-cell lymphoma (CTCL). Utilizing crystallography and structure-based drug design, BioCryst continues to discover additional compounds and to progress others through pre-clinical and early development to address the unmet medical needs of patients and physicians. The Company's strategic alliances with the U.S. Department of Health and Human Services, Shionogi & Co., Ltd., Green Cross Corporation and Mundipharma International Holdings Limited validate its scientific foundation and the utility of its product candidates. For more information, please visit the Company's Web site at www.biocryst.com.

------------------------------------------------------------------------------------------------------------------------------------------------------------ (NASDAQ: BCSI - Blue Coat Systems, Inc.) LATEST NEWS!! Blue Coat Announces Strategic Plan to Drive Long Term Revenue Growth and Increase Operating Profitability Company Confirms Net Revenue at High End of Guidance for Q2 2010, Agrees to Acquire S7 Software and Implements Corporate-Wide Restructuring SUNNYVALE, Calif., Nov 05, 2009 -- Blue Coat Systems, Inc. (Nasdaq: BCSI), the technology leader in Application Delivery Networking, today announced that it is implementing a strategic plan to drive future revenue growth and increase its non-GAAP operating profitability. This plan includes entry into an agreement to acquire S7 Software Solutions Pvt. Ltd., an IT research and development firm based in Bangalore, India. Upon the close of the transaction, S7 Software will serve as the Company's new development center in India. Blue Coat also announced a corporate-wide restructuring program that includes a net reduction in headcount of approximately 10 percent. The combination of the S7 Software acquisition and restructuring program is intended to enable the Company to more cost effectively develop new products and pursue new routes to market.

Blue Coat also announced preliminary, unaudited net revenue results for its second quarter of fiscal 2010, ended October 31, 2009, and confirmed that net revenue for its second fiscal quarter was toward the top end of its previous guidance of net revenue in the range of $116 to $121 million. Final results for the second fiscal quarter will be announced by the Company on Tuesday, November 24, 2009.

Blue Coat will hold a conference call today at 5:00 a.m. PT to discuss today's announcements - please see details at the end of this press release.

"Through the dedicated work of our employees and the capabilities of our existing products, we have earned the trust of our customers around the world and have attained market leadership," said Brian NeSmith, president and chief executive officer, Blue Coat Systems, Inc. "Our restructuring plan positions us to more aggressively and more profitably expand our vision for the Application Delivery Network." The restructuring plan will shift a number of engineering positions from Sunnyvale, Calif. and Austin, Texas to it other locations, such as the site it plans to acquire in Bangalore, India, through the S7 Software acquisition. It also involves the closure of three small facilities in Riga, Latvia; South Plainfield, New Jersey; and Zoetermeer, The Netherlands. Blue Coat is also reorganizing other functional areas, including sales and marketing, general and administrative, and support, to gain greater efficiencies.

"The combination of the restructuring program and the acquisition of S7 Software strikes an appropriate balance between profitability and investment for innovation," said Gordon Brooks, senior vice president and chief financial officer. "Together these actions will allow us to invest for future growth while aligning the Company's cost structure to its current revenue level, which should drive higher and more consistent levels of profitability." The Company's research and development work will now be undertaken at four sites that include: Sunnyvale, Calif.; Draper, Utah; Waterloo, Canada; and the new center in Bangalore, India. Each development center will be vertically integrated, so that each can assume full responsibility for the entire development process for each new or enhanced product or technology. Previously, projects crossed multiple design centers, resulting in a higher cost structure and slower time-to-market.

Blue Coat will pay US $5.25 million in cash to acquire all of the shares of S7 Software. S7 Software has approximately 50 engineers with expertise in software development, code migration and network security, and has distinguished as a top engineering company in India. The acquisition is subject to regulatory approval and is expected to close in the third quarter of Blue Coat's fiscal year 2010.

------------------------------------------------------------------------------------------------------------------------------------------------------------ (NASDAQ: BNVI - BioNovo, Inc..) LATEST NEWS!! Steven R. Goldstein, M.D., Joins Bionovo's Menerba Medical Advisory Board EMERYVILLE, Calif., Nov 05, 2009 -- Bionovo, Inc. (Nasdaq: BNVI) announced today the appointment of Steven R. Goldstein, M.D., to the company's Medical Advisory Board. Dr. Goldstein is a world leader on uterine safety. He has extensive experience in menopausal and perimenopausal uterine safety studies for several Selective Estrogen Receptor Modulators (SERMS).

"We are very excited to have Dr. Goldstein on the medical advisory board as we are advancing Menerba(TM) to Phase 3," said Mary Tagliaferri, M.D., L.Ac., Bionovo's President and Chief Medical Officer. She added, "Given the concern from the FDA regarding uterine safety in postmenopausal trials using traditional estrogen therapy, his groundbreaking work and expertise in menopausal ultrasounds will be highly pertinent during the Menerba Phase 3 trial." Dr. Goldstein states, "I look forward to working with Bionovo on the development of their novel estrogen receptor beta agonist drug, Menerba, for the treatment of postmenopausal vasomotor symptoms. Current estrogen treatments are associated with a 12 to 24 fold increase in uterine cancer; therefore alternative therapies are desperately needed for the treatment of hot flashes in postmenopausal women." Dr. Steven Goldstein is the current Director of Gynecologic Ultrasound at New York University Medical Center; he is the current 1st Vice President of the American Institute of Ultrasound in Medicine. He has authored many textbooks including: "Endovaginal Ultrasound", "Ultrasound in Gynecology" and "Textbook in Perimenopausal Gynecology". Additionally, he has authored more than a dozen textbook chapters as well as over 55 original research articles. He has been a guest faculty member, invited speaker, visiting professor or course director over 295 times in the United States and worldwide. He currently has authored two recently released books: "Could it Be... Perimenopause" and "The Estrogen Alternative." He is one of the most highly recognized and regarded individuals in the field of vaginal ultrasound.

Dr. Goldstein graduated Magna Cum Laude from Colgate University with a Baccalaureate degree in Biology. He graduated from the New York University School of Medicine in 1975 and completed his internship in Obstetrics and Gynecology at Parkland Memorial Hospital in Dallas, Texas from 1975-1976. He completed his residency in Obstetrics and Gynecology at New York University Affiliated Hospital/Bellevue Hospital Center from 1976-1980. He has been serving as clinical instructor at New York University School of Medicine since 1980 and full tenured Professor of Obstetrics and Gynecology since 1996.

Menerba Menerba is an estrogen receptor (ER) beta selective drug developed as an alternative to postmenopausal hormone products currently on the market, which are both ER beta and ER alpha agonists that have been shown to increase the risk for breast and uterine cancers. It has been shown that the increased risk of breast and uterine cancers is associated with ER alpha activation and that ER beta blocks the growth promoting effects on breast cancer cells. Bionovo recognized the opportunity to commercialize a product that would be equally effective, with an improved safety profile compared to traditional hormone therapy. The clinical trial results have been evaluated by an independent Data and Safety Monitoring Board and the drug candidate has passed through a standard two-phase examination for safety.

Bionovo, Inc.

Bionovo is a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, markets with significant unmet needs and billions in potential annual revenue. The company applies its expertise in the biology of menopause and cancer to design new drugs derived from botanical sources which have novel mechanisms of action. Based on the results of early and mid-stage clinical trials, Bionovo believes they have discovered new classes of drug candidates within their rich pipeline with the potential to be leaders in their markets. Bionovo is headquartered in Emeryville, California and is traded on the NASDAQ Capital Market under the symbol, "BNVI". For more information about Bionovo and its programs, visit http://www.bionovo.com.

------------------------------------------------------------------------------------------------------------------------------------------------------------ About StockMarketingInc.com StockMarketingInc.com is a website that profiles stocks of interest. We are not licensed brokers or financial consultants. The information here is believed to be reliable, but not guaranteed to be accurate by StockMarketingInc.com. Please be advised that the information contained may or may not be complete and is solely for informational purposes only. This is not to be construed as an offer to sell, hold or the solicitation of an offer to buy. Investors are encouraged to seek opinions by their registered brokers or financial advisors after extensive due diligence is performed.

((Comments on this story may be sent to info@m2.com)) (c) 2009 M2 COMMUNICATIONS

[ Back To TMCnet.com's Homepage ]









Technology Marketing Corporation

2 Trap Falls Road Suite 106, Shelton, CT 06484 USA
Ph: +1-203-852-6800, 800-243-6002

General comments: tmc@tmcnet.com.
Comments about this site: webmaster@tmcnet.com.

STAY CURRENT YOUR WAY

© 2020 Technology Marketing Corporation. All rights reserved | Privacy Policy